Palisade Bio
PALI
13 hedge funds and large institutions have $201K invested in Palisade Bio in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
30% more funds holding
Funds holding: 10 → 13 (+3)
1.75% less ownership
Funds ownership: 8.48% → 6.74% (-1.7%)
48% less capital invested
Capital invested by funds: $388K → $201K (-$187K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$46.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$34.4K |
| 3 |
HF
HRT Financial
New York
|
+$21.6K |
| 4 |
VF
Virtu Financial
New York
|
+$18K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$17.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$116K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$137 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $98.6K | +$46.6K | +39,397 | +37% |
|
|
2
UBS Group
Zurich,
Switzerland
| $25.9K | +$34.4K | +29,109 | +324% |
|
|
MG
3
Marex Group
London,
| $24.3K | – | – | – |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $16.8K | +$17.4K | +14,680 | +146% |
|
|
HF
5
HRT Financial
New York
| $12K | +$21.6K | +18,264 | New |
|
|
VF
6
Virtu Financial
New York
| $10K | +$18K | +15,255 | New |
|
|
TSS
7
Two Sigma Securities
New York
| $9.63K | +$16.7K | +14,153 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $3.11K | -$137 | -116 | -2% |
|
9
Morgan Stanley
New York
| $428 | +$734 | +621 | +8,871% |
|
|
FDCDDQ
10
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $68 | – | – | – |
|
11
Bank of America
Charlotte,
North Carolina
| $16 | +$15 | +13 | +130% |
|
12
Wells Fargo
San Francisco,
California
| $14 | – | – | – |
|
13
Barclays
London,
United Kingdom
| $4 | +$7 | +6 | New |
|
|
14
Cetera Investment Advisers
Schaumburg,
Illinois
| – | -$116K | -70,006 | Closed |
|
PALI Hedge Fund Activity: Q1 2025 in Review
13 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2025, worth a combined $201K — down 48% from $388K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PALI positions and 1 closed out — a net gain of 3 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $46.6K. The largest seller was Cetera Investment Advisers, exiting entirely with an estimated $116K sold.
- 13 institutional investors held Palisade Bio (PALI) as of Q1 2025, up from 10 in Q4 2024.
- Funds reported $201K of Palisade Bio stock for Q1 2025, down 48% quarter-over-quarter.
- 4 funds opened new Palisade Bio positions in Q1 2025 and 1 closed out, a net change of +3 holders.
- The largest Palisade Bio buyer in Q1 2025 was Armistice Capital, an estimated $46.6K added.
- The largest Palisade Bio seller in Q1 2025 was Cetera Investment Advisers, an estimated $116K sold.
Based on aggregated 13F filings for Q1 2025.